319 related articles for article (PubMed ID: 16875469)
1. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.
Kranz G; Sycha T; Voller B; Gleiss A; Schnider P; Auff E
Dermatol Surg; 2006 Jul; 32(7):886-90. PubMed ID: 16875469
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
3. Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study.
Rystedt A; Karlqvist M; Bertilsson M; Naver H; Swartling C
Acta Derm Venereol; 2013 Nov; 93(6):674-8. PubMed ID: 23694974
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
6. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
7. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
Benecke R; Heinze A; Reichel G; Hefter H; Göbel H;
Pain Med; 2011 Nov; 12(11):1607-14. PubMed ID: 21692970
[TBL] [Abstract][Full Text] [Related]
8. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations.
Rystedt A; Swartling C; Naver H
Acta Derm Venereol; 2008; 88(3):229-33. PubMed ID: 18480920
[TBL] [Abstract][Full Text] [Related]
9. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
Rystedt A; Swartling C; Färnstrand C; Naver H
Acta Derm Venereol; 2008; 88(5):458-61. PubMed ID: 18779882
[TBL] [Abstract][Full Text] [Related]
10. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
Vadoud-Seyedi J; Simonart T
Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
[TBL] [Abstract][Full Text] [Related]
12. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
Göbel H; Heinze A; Reichel G; Hefter H; Benecke R;
Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
[TBL] [Abstract][Full Text] [Related]
14. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
Farahvash MR; Arad S
J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
[TBL] [Abstract][Full Text] [Related]
15. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study.
Kranz G; Paul A; Voller B; Posch M; Windischberger C; Auff E; Sycha T
Br J Dermatol; 2011 Jan; 164(1):176-81. PubMed ID: 21039405
[TBL] [Abstract][Full Text] [Related]
17. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
Rosales RL; Ng AR; Santos MM; Fernandez HH
Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
Nüssgens Z; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
[TBL] [Abstract][Full Text] [Related]
19. Is there a direct antimicrobial effect of botulinum neurotoxin type A?
Wöllner J; Schmidig K; Gregorini F; Kessler TM; Zbinden R; Mehnert U
BJU Int; 2012 Dec; 110(11 Pt C):E886-90. PubMed ID: 22882378
[TBL] [Abstract][Full Text] [Related]
20. Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain.
Mahowald ML; Krug HE; Singh JA; Dykstra D
Toxicon; 2009 Oct; 54(5):658-67. PubMed ID: 19351542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
